Zimbabwe faces challenges in preventing, treating cervical cancer, PlusNews reports

NewsGuard 100/100 Score

"HIV-positive women are living longer, but are now dying of cervical cancer," and "[i]n Zimbabwe, cervical cancer is now the most common cancer among women, particularly those living with HIV," PlusNews reports. "According to the Zimbabwe National Cancer Registry, cervical cancer affects about 30 percent of women in the country," the news service notes, adding the WHO says "[a]bout 1,900 women are diagnosed with the disease every year in Zimbabwe and 1,300 die."

PlusNews details the challenges to fighting cervical cancer in the country, including a lack of monetary resources, non-functioning diagnostic equipment, and a paucity of treatments. "Minister of Health and Child Welfare Henry Madzorera admitted that lack of funds had stymied the roll-out of a cervical cancer vaccine early this year, but said the government would be mobilizing funds from donors to launch the vaccine in 2014," the news service writes, adding, "Meanwhile, he said, the government would focus on other strategies to reduce cervical cancer deaths in the country, such as screening and testing and treatment for those infected" (2/8).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New trials show promise for immune checkpoint blockers in early-stage lung cancer